Ramipril Reduces Acylcarnitines and Distinctly Increases Angiotensin-Converting Enzyme 2 Expression in Lungs of Rats
The angiotensin-converting enzyme 2 (ACE2) receptor has been identified as the entry receptor for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is abundantly expressed in many organs. With respect to the role of circulating ACE2 and its receptor expression in the pathogenesis...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Metabolites |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-1989/12/4/293 |
| _version_ | 1827627684059938816 |
|---|---|
| author | Joanna Kosacka Claudia Berger Uta Ceglarek Anne Hoffmann Matthias Blüher Nora Klöting |
| author_facet | Joanna Kosacka Claudia Berger Uta Ceglarek Anne Hoffmann Matthias Blüher Nora Klöting |
| author_sort | Joanna Kosacka |
| collection | DOAJ |
| description | The angiotensin-converting enzyme 2 (ACE2) receptor has been identified as the entry receptor for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is abundantly expressed in many organs. With respect to the role of circulating ACE2 and its receptor expression in the pathogenesis of the SARS-CoV-2 infection, it is still debated whether diseases such as hypertension or pharmacotherapies, including ACE inhibitors and angiotensin receptor blockers that affect ACE2 receptor expression, may modulate the severity and outcome of the coronavirus disease 2019 (COVID-19). We therefore tested the hypothesis that treatment with the ACE inhibitor Ramipril affects organ-specific ACE2 receptor mRNA and protein expression as well as the serum metabolome in BioBreeding (BB) rats. Twelve male BioBreeding rats were randomly divided into a Ramipril (10 mg/kg body weight) treatment group or a control group (<i>N</i> = 12; <i>n</i> = 6 per group) over a period of seven days. Ramipril treatment resulted in the reduction of acylcarnitines (C3–C6) out of 64 metabolites. Among the different organs studied, only in the lungs did Ramipril treatment significantly increase both <i>Ace2</i> mRNA and ACE2 receptor membrane protein levels. Increased ACE2 receptor lung expression after Ramipril treatment was not associated with differences in ACE2 serum concentrations between experimental groups. Our data provide experimental in vivo evidence that the ACE inhibitor Ramipril selectively increases pulmonary ACE2 receptor mRNA and protein levels and reduces acylcarnitines. |
| first_indexed | 2024-03-09T13:19:25Z |
| format | Article |
| id | doaj.art-648c5212a2bf4966888cc25a9e60f45c |
| institution | Directory Open Access Journal |
| issn | 2218-1989 |
| language | English |
| last_indexed | 2024-03-09T13:19:25Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Metabolites |
| spelling | doaj.art-648c5212a2bf4966888cc25a9e60f45c2023-11-30T21:31:51ZengMDPI AGMetabolites2218-19892022-03-0112429310.3390/metabo12040293Ramipril Reduces Acylcarnitines and Distinctly Increases Angiotensin-Converting Enzyme 2 Expression in Lungs of RatsJoanna Kosacka0Claudia Berger1Uta Ceglarek2Anne Hoffmann3Matthias Blüher4Nora Klöting5Medical Department III—Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Liebigstr. 20, 04103 Leipzig, GermanyMedical Department III—Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Liebigstr. 20, 04103 Leipzig, GermanyInstitute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, Leipzig University Medical Center, 04103 Leipzig, GermanyHelmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig, Ph.-Rosenthal-Str. 27, 04103 Leipzig, GermanyMedical Department III—Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Liebigstr. 20, 04103 Leipzig, GermanyHelmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig, Ph.-Rosenthal-Str. 27, 04103 Leipzig, GermanyThe angiotensin-converting enzyme 2 (ACE2) receptor has been identified as the entry receptor for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is abundantly expressed in many organs. With respect to the role of circulating ACE2 and its receptor expression in the pathogenesis of the SARS-CoV-2 infection, it is still debated whether diseases such as hypertension or pharmacotherapies, including ACE inhibitors and angiotensin receptor blockers that affect ACE2 receptor expression, may modulate the severity and outcome of the coronavirus disease 2019 (COVID-19). We therefore tested the hypothesis that treatment with the ACE inhibitor Ramipril affects organ-specific ACE2 receptor mRNA and protein expression as well as the serum metabolome in BioBreeding (BB) rats. Twelve male BioBreeding rats were randomly divided into a Ramipril (10 mg/kg body weight) treatment group or a control group (<i>N</i> = 12; <i>n</i> = 6 per group) over a period of seven days. Ramipril treatment resulted in the reduction of acylcarnitines (C3–C6) out of 64 metabolites. Among the different organs studied, only in the lungs did Ramipril treatment significantly increase both <i>Ace2</i> mRNA and ACE2 receptor membrane protein levels. Increased ACE2 receptor lung expression after Ramipril treatment was not associated with differences in ACE2 serum concentrations between experimental groups. Our data provide experimental in vivo evidence that the ACE inhibitor Ramipril selectively increases pulmonary ACE2 receptor mRNA and protein levels and reduces acylcarnitines.https://www.mdpi.com/2218-1989/12/4/293ACE2lungsRamiprilSARS-CoV-2C3MC4M |
| spellingShingle | Joanna Kosacka Claudia Berger Uta Ceglarek Anne Hoffmann Matthias Blüher Nora Klöting Ramipril Reduces Acylcarnitines and Distinctly Increases Angiotensin-Converting Enzyme 2 Expression in Lungs of Rats Metabolites ACE2 lungs Ramipril SARS-CoV-2 C3M C4M |
| title | Ramipril Reduces Acylcarnitines and Distinctly Increases Angiotensin-Converting Enzyme 2 Expression in Lungs of Rats |
| title_full | Ramipril Reduces Acylcarnitines and Distinctly Increases Angiotensin-Converting Enzyme 2 Expression in Lungs of Rats |
| title_fullStr | Ramipril Reduces Acylcarnitines and Distinctly Increases Angiotensin-Converting Enzyme 2 Expression in Lungs of Rats |
| title_full_unstemmed | Ramipril Reduces Acylcarnitines and Distinctly Increases Angiotensin-Converting Enzyme 2 Expression in Lungs of Rats |
| title_short | Ramipril Reduces Acylcarnitines and Distinctly Increases Angiotensin-Converting Enzyme 2 Expression in Lungs of Rats |
| title_sort | ramipril reduces acylcarnitines and distinctly increases angiotensin converting enzyme 2 expression in lungs of rats |
| topic | ACE2 lungs Ramipril SARS-CoV-2 C3M C4M |
| url | https://www.mdpi.com/2218-1989/12/4/293 |
| work_keys_str_mv | AT joannakosacka ramiprilreducesacylcarnitinesanddistinctlyincreasesangiotensinconvertingenzyme2expressioninlungsofrats AT claudiaberger ramiprilreducesacylcarnitinesanddistinctlyincreasesangiotensinconvertingenzyme2expressioninlungsofrats AT utaceglarek ramiprilreducesacylcarnitinesanddistinctlyincreasesangiotensinconvertingenzyme2expressioninlungsofrats AT annehoffmann ramiprilreducesacylcarnitinesanddistinctlyincreasesangiotensinconvertingenzyme2expressioninlungsofrats AT matthiasbluher ramiprilreducesacylcarnitinesanddistinctlyincreasesangiotensinconvertingenzyme2expressioninlungsofrats AT norakloting ramiprilreducesacylcarnitinesanddistinctlyincreasesangiotensinconvertingenzyme2expressioninlungsofrats |